Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarithromycin-added PCd versus PCd in relapsed or refractory multiple myeloma
ChiCTR2100047608Phase 4Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clarithromycin, pomalidomide, cyclophosphamide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Overall response rate. Started Jul 2021; status: recruiting.
02
Drugs
clarithromycinpomalidomidecyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100047608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047608.